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ABSTRACT 
We previously reported the identification of a novel family of immunomodulatory proteins 
(termed helminth defence molecules; HDMs) that are secreted by medically-important 
trematode parasites. Since HDMs share biochemical, structural and functional characteristics 
with mammalian cathelicidin-like host defence peptides (HDPs), we proposed that HDMs 
modulate the immune response via molecular mimicry of host molecules. In the present 
study, we report the mechanism by which HDMs influence the function of macrophages. We 
show that the HDM secreted by Fasciola hepatica (FhHDM-1) binds to macrophage plasma 
membrane lipid rafts via selective interaction with phospholipids and/or cholesterol, before 
being internalised by endocytosis. Following internalisation, FhHDM-1 is rapidly processed 
by lysosomal cathepsin L to release a short C-terminal peptide (containing a conserved 
amphipathic helix that is key to HDM function) which then prevents the acidification of the 
endolysosomal compartments by inhibiting vacuolar (v) ATPase activity. The resulting 
endolysosomal alkalisation impedes macrophage antigen processing and prevents the 
transport of peptides to the cell surface in conjunction with MHC class II for presentation to 
CD4+ T cells. Thus, we have elucidated a novel mechanism by which helminth pathogens 
alter innate immune cell function to assist their survival in the host. 
 
 
Key Words: Trematode, Fasciola hepatica, macrophage, lysosomal acidification, host 
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4 
 
INTRODUCTION 
The innate immune response represents the first line of defence against invading pathogens. 
In addition to roles in direct recognition and engulfment of pathogens, macrophages promote 
antigen-specific adaptive immune responses. Pathogen antigens phagocytosed by 
macrophages undergo partial proteolysis by lysosomal peptidases before being loaded onto 
major histocompatibility complex (MHC) class II molecules for presentation to CD4
+
 T cells 
(1), thereby generating both effector and memory immune responses. Thus, macrophages are 
critical in establishing communication between the innate and adaptive immune systems, and, 
in doing so largely determine the nature of the adaptive immune responses mounted which 
ensures that pathogens are either eliminated or their pathological effects are minimised.   
 Host defence peptides (HDPs; also referred to as antimicrobial peptides (AMPs) when 
they possess direct antimicrobial activity) represent an evolutionarily conserved component 
of innate immunity (2). To date, over 1000 naturally-occurring HDPs/AMPs have been 
identified displaying great diversity in sequence lengths, structures and activities (3). Since 
HDPs/AMPs share only limited sequence identity, they are broadly classified on the basis of 
homologous secondary structure as cathelicidins (linear α-helical peptides), defensins (β-
strand peptides connected by disulfide bonds), and bactenecins (loop peptides) (4). Despite 
such variation, HDPs/AMPs are generally cationic with hydrophobic faces (5,6), allowing 
many of them to interact with, and disrupt, negatively charged microbial cell membranes  
(7).  
Helminth parasites have devised many mechanisms for manipulating the responses of 
their hosts to allow their survival for long periods, and these often involve the secretion of 
specific molecules (8). We recently reported the identification of a novel immunomodulatory 
molecule secreted by the animal and human pathogen Fasciola hepatica (termed helminth 
defence molecule; FhHDM-1) that exhibits structural, biochemical and functional 
characteristics similar to mammalian cathelicidin-like HDPs (9). Phylogenetic analysis 
revealed that FhHDM-1 represented an archetypal member of a family of HDMs conserved 
throughout the Trematoda which includes major parasitic helminths of humans such 
Schistosoma mansoni, S. japonicum, Opisthorchis viverrini, Clonorchis sinensis and 
Paragonimus westermani. We isolated native and recombinant FhHDM-1 and showed that, 
like the mammalian cathelicidins, the precursor parent molecule is proteolytically processed 
(in this case by the parasite endopeptidase, cathepsin L1), to release a 34-residue C-terminal 
peptide (FhHDM p2) that forms an amphipathic helix. We proposed that the secretion of 
5 
 
HDMs represented an exquisite example of parasite immunomodulation mediated by the 
secretion of a host-like molecular mimic that influences host innate immune responses. 
Indeed, we demonstrated that both FhHDM-1, and FhHDM-1 p2 protected mice against LPS-
induced inflammation by preventing the activation of macrophages (9).  
 In the present study, we investigated the mechanism by which HDMs influence the 
function of macrophages. Our studies show that FhHDM-1 binds to macrophage plasma 
membrane lipid rafts, via selective interaction with phospholipids and/or cholesterol before 
being internalised by endocytosis. Following internalisation, FhHDM-1 is rapidly processed 
by lysosomal cathepsin L to release a 27 amino acid C-terminal peptide (containing the 
conserved amphipathic helix), which then prevents the acidification of the endolysosomal 
compartments by inhibiting vacuolar (v) ATPase activity. Preventing endolysosomal 
acidification impedes macrophage antigen processing by proteases, such as cathepsin L, 
preventing the presentation of peptides at the cell surface in conjunction with MHC class II to 
CD4+ T cells. Thus, we have elucidated a novel mechanism by which helminth pathogens 
alter innate immune cell function to prevent the development of effective adaptive immune 
responses, thereby ensuring prolonged parasite survival in the host. 
 
MATERIALS AND METHODS 
Recombinant FhHDM-1 and synthetic peptide analogues 
Recombinant FhHDM-1 was expressed in E. coli and purified as previously described (9). 
Residual bacterial endotoxin was removed from all samples using RP-HPLC. Final endotoxin 
levels were measured using the Chromo-LAL assay kit (Associates of Cape Cod, East 
Falmouth, MA, USA) and shown to be 0.0029 EU/µg.  
A number of peptides were prepared based on the C-terminal alpha amphipathic helix 
of FhHDM-1 (Fig. 1). FhHDM-1 peptide 1 (FhHDM-1 p1) corresponds to residues 51-80, 
and represents a truncation of the C-terminal amphipathic helix. FhHDM-1 p2 corresponds to 
residues 56-89 and matches the C-terminal fragment of FhHDM-1 containing the complete 
amphipathic helix that is released following cleavage by FhCL1 (9). FhHDM-1 2Pro also 
corresponds to residues 56-89, but contains two proline substitutions (I69P and L80P) 
designed to disrupt the α-helix. Similarly, FhHDM-1 nonHP corresponds to residues 56-89 
but contains six substitutions (I69R, I73Q, I75K, L76R, L84T and Y87K) designed to abolish 
the hydrophobic face of the amphipathic helix whilst preserving the α-helix. FhHDM-1 p3 
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matches the C-terminal fragment of FhHDM-1 containing the complete amphipathic helix 
that is released following cleavage by lysosomal cysteine peptidases as identified in the 
present study. The molar concentration of the HDM-derived peptides used is presented in 
Fig. S1. 
HDM peptides were labelled with Cy5 (GE Healthcare, Pittsburgh, PA) or Alexa 
Fluor 488 (Life Technologies, Vic, Australia) according to the manufacturer`s instructions. 
All peptides were synthesised endotoxin-free by GL Biochem (Shanghai, China).  
 
Primary human macrophages 
Monocytes were isolated from buffy coats obtained from normal healthy adult donors and 
supplied by the Australian Red Cross Blood Service (Sydney, Australia). Mononuclear cells 
were purified from buffy coats by Ficoll-paque separation then CD14+ monocytes were 
enriched by positive selection (Miltenyi Biotec). Monocytes were differentiated into 
macrophages for up to 7 days in Iscove’s Modified Dulbecco’s Media (IMDM) supplemented 
with 2 % v/v human serum and their phenotype confirmed (expression of CD206) using an 
LSR II flow cytometer (BD Bioscience). 
 
Confocal laser scanning microscopy 
For confocal laser scanning microscopy (CLSM) experiments, human primary macrophages 
(1x10
6
) derived from blood monocytes (Australian Red Cross, Sydney, Australia) were 
treated with 10 μg/mL of recombinant FhHDM-1 at 37ºC then washed and fixed with 4% 
paraformaldehyde and permeabilized with 0.1% Triton-X/PBS. After blocking, cells were 
incubated for 1 h at room temperature with primary antibody (1:2000) specific for His6 tag 
(Life Technologies, Vic Australia). Cells were then washed and incubated with Alexa Fluor 
488-conjugated (Life Technologies, Vic Australia) secondary antibody. To follow 
internalisation of FhHDM-1, macrophages (7x10
5
) were simultaneously incubated with 10 
μg/mL of Alexa Fluor 488-labelled FhHDM-1 and 60 nM LysoTracker (Life Technologies, 
Vic, Australia) for 45 min at 37ºC.   
To examine the effect of FhHDM-1 on lysosome formation, macrophages (1x10
6
) 
were incubated with either recombinant FhHDM-1 (10 μg/mL) or vehicle (PBS) for 20 h at 
37ºC. After washing, cells were incubated with E. coli LPS (50 ng/mL; serotype 111:B4; 
Sigma, NSW Australia) for 2 h and stained with LysoTracker, according to the 
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manufacturer`s instructions. The cells were mounted in VectaShield
®
 (Vector Laboratories, 
Burlingame, CA, USA) and examined with a Nikon A1 confocal scanning laser microscope. 
Images were rendered and analysed using NIS Elements software (Nikon, Melville, NY, 
USA).  
 
3D-Structured Illumination Microscopy 
Human primary macrophages (1x10
6
) were treated with recombinant FhHDM-1 (10 μg/mL) 
for 2 h. Cells were incubated with 4 g/mL of cholera toxin subunit B Alexa Fluor 594-
conjugate (CT-B) for 20 min at 4°C, then fixed, and stained for FhHDM-1 using the His6 
antibody as described above. Imaging was performed using a DeltaVisionOMX 3D-
Structured Illumination Microscope
®
, version 3 (OMX 3D-SIM, Applied Precision Inc, 
Issaquah, USA). Solid state lasers (405, 488, 593 nm) were captured simultaneously using 3 
Photometrics Cascade (Photometrics, Tucson, USA) back- illuminated EMCCD cameras 
(>90% QE) with a 512 x 512 CCD, and on-chip charge multiplication. All data capture used 
an Olympus UPlanSApo 100x 1.4NA oil objective and standard excitation and emission filter 
sets (in nm, 405 EX / 419-465 EM, 488 EX / 500-550 EM and 592.5 EX / 608-648 EM). 3D-
SIM images were sectioned using a 125 nm Z-step size. Raw 3-phase images were 
reconstructed as previously described (10,11) and the reconstructed images were rendered in 
3D, with interpolation, using IMARIS v.7 software (Bitplane Scientific, Zurich, Switzerland). 
 
Flow cytometry 
RAW264.7 macrophages (1x10
6
/well) were cultured in 24-well plates with or without 0.25 
g/mL trypsin (Life Technologies) for 1 h at 37°C. After washing, cells were incubated with 
Cy5-labelled recombinant FhHDM-1 (10 g/mL) for 30 min at 4°C. Binding of Cy5-
FhHDM-1 and was assessed by flow cytometry. Cells were also stained for the surface 
markers CD11b and F4/80 using directly conjugated FITC-monoclonal antibodies (BD 
Bioscience, San Jose, CA, USA).  
 
Sodium carbonate membrane extraction 
RAW264.7 macrophages (2x10
7
) were incubated with 20µg/mL of recombinant FhHDM-1 at 
37°C for 2 h followed by cross-linking with 1% paraformaldehyde for 30 minutes. After 
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sonication, membranes were prepared by centrifugation at 20,000g for 1 h. The membrane 
pellet was sequentially extracted with 0.1M Na2CO3 (pH 11) and 1 % Triton X100 (TX100) 
to produce peripheral and integral membrane protein fractions respectively (12). Samples 
were separated by non-reducing SDS-PAGE, transferred to nitrocellulose membranes and 
probed with anti-FhHDM-1 (9), anti-actin, and anti-calnexin antibodies (Sigma, NSW 
Australia). 
 
HDM-liposome interaction assay 
Large uni-lamellar liposome vesicles (LUVs) composed of the phospholipids 1-palmitoyl-2-
oleoyl-sn-glycero-3-phosphatidylcholine (POPC), 1-palmitoyl-2-oleoyl-sn-glycerol-3-
phosphatidylserine (POPS) and 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphatidylethanolamine 
(POPE) in a 3:1:1 molar ratio (Avanti Polar Lipids, Alabaster, AL) were made via the 
extrusion method (13) in 10% sucrose. HDMs (50 M) were incubated with the LUVs for 2 h 
at 37C before separation overnight on a discontinuous sucrose gradient (100,000g) at 4C. 
Fractions were taken from the top (LUVs) and bottom of the tube and run in reducing 4-12% 
NuPage Bis-Tris gels (Life Technologies, Vic, Australia). Gels were silver-stained and 
imaged with a PharosFX laser imaging system (Bio-Rad, NSW Australia). 
 
Phospholipid ELISA 
PolySorp 96-well plates (Nunc, Roskilde, Denmark) were coated, in triplicate, with 200 µL 
of 100µg/mL lipids (sphingomyelin, POPC, POPS, POPE, 1,2-dioleoyl-sn-glycero-3-
phosphatidylcholine (DOPC) as well as cholesterol) dissolved in ethanol and dried under 
nitrogen gas overnight (14). Plates were washed then incubated with serially diluted 
biotinylated FhHDM-1 p2 for 90 min at 37°C. Plates were washed and bound proteins were 
detected with ExtrAvidin-AP with pNPP substrate (Sigma, NSW, Australia).  
 
Phagocytosis assays 
Human primary macrophages or RAW264.7 cells were treated with HDMs (10 g/ml) for 20 
h or 1 h with folimycin (1 M; Merck, NSW, Australia) or NH4Cl (20 mM). In some 
experiments, cells were treated with E-64 (10 M; Sigma, NSW, Australia) for 30 min prior 
to stimulation with recombinant FhHDM-1 for 3 h. Cells were then washed and incubated 
with 125g/ml E. coli pHrodo Bioparticles (Life Technologies, Vic, Australia) for 2 h at 
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37°C and fluorescence from phagocytosed bioparticles was read using a Bio-Tek KC4 
microfluorometer (532 nm excitation and 585 nm emission). Net phagocytosis was calculated 
relative to PBS-treated cells (equivalent to 100% phagocytosis). Phagocytosis of zymosan 
particles by RAW264.7 cells was determined using the CytoSelect 96-Well Phagocytosis 
Assay (Cell Biolabs Inc. San Diego, CA, Australia), according to the manufacturer`s 
instructions. To visualise phagocytosis, cells (1x10
6
) were treated with or without Alexa 
Fluor 488-conjugated FhHDM-1 (50 μg/mL) for 2 h at 37ºC followed by Alexa Fluor 647-
conjugated dextran (10 μg/mL; Life Technologies, Vic, Australia) for 2 h at 37ºC. Cells were 
washed and fixed before imaging by CLSM.  
 
Enrichment of lysosomal membranes  
The method of Cohen et al. (15) was used to prepare a fraction enriched 10x for lysosomes. 
Briefly, THP-1 or RAW264.7 macrophages (4x10
7
) were sonicated on ice and a post-nuclear 
supernatant further centrifuged at 100,000g for 20 min to pellet lysosomes and endosomes. 
The lysosome pellet was extracted with water for 5 min then centrifuged at 100,000g for 20 
min. The supernatant was collected as the lysosome-soluble fraction (Ly-S) and the pellet as 
lysosome-insoluble membrane fraction (Ly-M). The Ly-M pellet was resuspended in 10 mM 
Tris acetate (pH 7.0) overnight at 4°C. The Ly-S and Ly-M fractions were analysed by 
Western blot, for LAMP1 expression, using a specific antibody (Abcam, Cambridge, MA, 
USA).  
 
Purification of phagosomes using latex beads 
The method of Shui et al. (16) was used to isolate phagosomes. Briefly, RAW264.7 
macrophages were incubated with 0.8 M deep blue-dyed latex beads (Sigma, NSW, 
Australia) and allowed to internalize for 2 h at 37°C. The bead-containing phagosomes were 
purified using a sucrose gradient as described by Desjardins et al. (17). Soluble and 
membrane protein fractions were prepared from the washed phagosomes as described above. 
 
ATPase assay 
ATPase activity was detected in macrophage Ly-M fractions using the ATPase Assay kit 
(Innova Biosciences, Babraham, Cambridge, UK) according to the manufacturer`s 
instructions. For inhibition assays, serial dilutions of HDMs were pre-incubated with Ly-M in 
0.1 M Tris-HCl (pH 7.5) for 1 h at 37°C prior to incubation with the ATP substrate. 
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Processing of FhHDM-1 by macrophage lysosomal proteases 
Lysosomal cathepsin activity in macrophage extracts was confirmed by incubating the 
soluble extract fraction (Ly-S) with the fluorogenic substrate Z-Leu-Arg-NHMec (Bachem, 
Bubendorf, Switzerland). Assays were performed (± 10 M E-64) at pH 5.5 as previously 
described (18).  
 Processing of FhHDM-1 was analysed by mixing 25 g of the recombinant with 
RAW264.7 macrophage-derived Ly-S (1 g protein) in 0.1 M sodium acetate (pH 5.5) 
containing 1 mM EDTA and 1 mM DTT for up to 5 h at 37 °C. Reactions were stopped by 
the addition of E-64 (10 μM). Digests were also performed using purified native human 
cathepsin L (Abcam, Cambridge, MA, USA). Samples were run on 4–12% Bis-Tris gels 
(Life Technologies, Vic Australia), transferred to nitrocellulose membranes and probed with 
an anti-FhHDM-1 antibody (9).  
 To identify peptides resulting from proteolytic processing of FhHDM-1, samples of 
the 0 h, 2 h and 5 h Ly-S digests were analysed by Matrix Assisted Laser Desorption 
Ionisation (MALDI) mass spectrometry at the Australian Proteome Analysis Facility as 
previously described (9). Spectra were acquired in positive mode in the mass range 2,000-
20,000 Da with a mass accuracy of ± 50 Da.   
 
Antigen processing assays 
Bone marrow-derived macrophages (BMDMs) were generated from the femurs of BALB/c 
mice and confirmed to be F4/80
+
CD11b
+
 by flow cytometry. FITC-conjugated casein (50 
g/ml) was fed to RAW264.7 macrophages or BMDMs (3 x 106) with or without HDMs (5, 
20 and 50 g/ml) or chloroquine (20 M). After 3 h incubation at 37°C, the cells were 
washed then lysed in RIPA buffer supplemented with protease inhibitor cocktail (Roche, 
NSW, Australia). Lysates were normalised for protein content and run on 4-12 % Bis-Tris 
gels (Life Technologies, Vic, Australia). Gels were scanned in the FITC channel using a 
PharosFX laser imaging system and normalized spot quantities were determined using 
PDQuest version 8.01 software (Bio-Rad, NSW, Australia). 
 
Antigen presentation assays 
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BMDMs (1 x 10
5
) were treated with HDMs (10-100 g/ml) for 2 h then pulsed overnight 
with 10 mg/ml full-length ovalbumin (OVA; Sigma, NSW, Australia) or pre-processed 
OVA
323-339
 peptide (Anaspec, Fremont, CA, USA). The HDM-treated OVA-pulsed BMDMs 
were then co-cultured with 1 x 10
5
 DO-11-10 T cell hybridomas (ECACC) for 24 h and 
levels of IL-2 in the culture medium measured by ELISA (BD Pharmingen, NSW, Australia).  
 
RESULTS 
FhHDM-1 binds to the macrophage plasma membrane via interaction with lipid rafts 
To investigate how the cathelicidin-like molecule secreted by F. hepatica interacts with 
macrophages, we first incubated primary human macrophages with recombinant FhHDM-1 
and examined its cellular localisation pattern using an anti-His6 tag antibody. No fluorescence 
was observed in PBS-treated cells stained with the anti-His6 tag antibody (Fig. 2A), which 
confirms the specificity of the antibody for recombinant FhHDM-1. After 30 min incubation, 
fluorescence could be seen around the periphery of the cells, the intensity of which became 
stronger and distinctly punctate after 1 and 2 h (Fig. 2A).  Localisation of the FhHDM-1 
fluorescence at the macrophage plasma membrane was confirmed by counterstaining the cells 
with the lipophilic dye, DiI (Fig. 2A). When cells were incubated with an alternative His-
tagged recombinant protein (FhCL1) (19), no surface labeling was observed, which 
demonstrates the specificity of the interaction of FhHDM-1 with the plasma membrane (Figs. 
S2A and S2B). Furthermore, OMX 3D-SIM microscopy revealed strong co-localisation of 
FhHDM-1 with the fluorescent lipid raft marker, CT-B (Fig. 2B; yellow fluorescence), 
indicating that FhHDM-1 interacts specifically with lipid rafts within the plasma membrane 
of primary human macrophages. FhHDM-1 also co-localised with CT-B on the surface of 
murine RAW264.7 macrophages (data not shown) demonstrating that its association with 
lipid rafts is not confined to human cells. 
 
FhHDM-1 makes electrostatic interactions with the macrophage plasma membrane that are 
not associated with protein/receptor-binding 
To investigate the biochemical nature of the FhHDM-lipid raft interaction, we performed an 
extraction of membranes, prepared from RAW264.7 macrophages treated with FhHDM-1. 
When membrane proteins are associated through electrostatic forces (typical of both 
receptor–ligand interactions and peripheral membrane proteins), these complexes are easily 
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disrupted and dissociated from the membrane. If, however, the protein is integral and 
associates with the membrane through hydrophobic interactions with the acyl core of the lipid 
bilayer, it will be highly resilient to dissociation. As expected, the peripheral membrane 
protein actin was only recovered in the Na2CO3 aqueous fraction of the RAW264.7 
macrophages (Fig. 3A). By contrast, calnexin, which is an integral membrane protein, was 
found predominantly in the TX100 detergent fraction (Fig. 3A). FhHDM-1 was only 
recovered in the Na2CO3 aqueous fraction (Fig. 3A) suggesting that it interacts with plasma 
membrane/lipid raft components via electrostatic interactions. A similar result was obtained 
using membranes isolated from human THP-1 macrophages (Fig. S2C).  
 Having established that FhHDM-1 binds the macrophage plasma membrane via 
electrostatic interactions, we next investigated whether this was indicative of 
protein/receptor-binding. To investigate this, RAW264.7 macrophages were incubated ± 
trypsin for 1 h at 37°C and the surface binding of Cy5-FhHDM-1 determined by flow 
cytometry. Immunostaining for the macrophage surface markers, CD11b and F4/80, was used 
to demonstrate the success of trypsinisation. As expected, CD11b and F4/80 fluorescence was 
markedly decreased in trypsinised macrophages compared with undigested cells (Fig. 3B) 
showing that trypsin effectively degraded surface expressed membrane proteins.  In contrast, 
the ability of FhHDM-1 to bind to the macrophage surface was unaffected following 
trypsinization as the level of Cy5-fluorescence was almost identical in digested and 
undigested cells (Fig. 3B), suggesting that FhHDM-1 does not associate with surface-
expressed macrophage proteins (at least those susceptible to trypsinization).  
 Having established that FhHDM-1 did not likely interact with proteins expressed on 
the macrophage surface we examined its potential to bind directly to phospholipid or other 
non-protein components of the plasma membrane. To assess whether FhHDM-1 interacts 
with membranes, LUVs composed of common phospholipids, were used as model 
membranes.  As shown by silver-stained SDS-PAGE, FhHDM-1 bound directly to the LUVs, 
whereas the control protein BSA was found at the bottom of the gradient (Fig. 3C).  
 
A peptide corresponding to the conserved amphipathic helix of FhHDM-1 binds to liposomes 
FhHDM-1 p2 is a 34 amino acid peptide containing the complete amphipathic helix of 
FhHDM-1 and is specifically released by proteolytic processing of the protein by the parasite 
protease FhCL1 (9). Like the parent molecule, this peptide bound to LUVs. In contrast, 
FhHDM-1 nonHP, which is similar to FhHDM-1 p2 but has six amino acid substitutions that 
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abolish the hydrophobic face of the amphipathic helix, did not associate with the LUV 
fraction but was instead detected in the bottom fraction of the sucrose gradient (Fig. 3C). This 
demonstrates the importance of the C-terminal amphipathic helix of FhHDM-1 for the 
association of this protein with cell-surface lipids.  
 We next investigated if the amphipathic helix preferentially bound particular 
phospholipid species. Monolayers of common phospholipids and cholesterol were prepared 
in ELISA plates and the binding of serially diluted biotinylated FhHDM-1 p2 was detected 
with a streptavidin-AP conjugate. The highest level of binding by FhHDM-1 p2 was to 
POPS, followed by DOPC and cholesterol (Fig. 3D). In contrast, FhHDM-1 p2 showed 
weaker binding to POPE and little or no reactivity with POPC and sphingomyelin (Fig. 3D). 
Sphingomyelin, POPC, and DOPC represent disaturated, monosaturated, and unsaturated 
phosphocholine lipids, respectively. FhHDM-1 p2 bound to DOPC (unsaturated) but also 
showed a high level of binding to POPS (monosaturated). This suggests that the selective 
phospholipid-binding properties of FhHDM-1 p2 are not simply due to lipid saturation status 
or to the presence of specific charged head groups in a particular lipid. Rather, binding ability 
appears to be related to the differential spacing of the head groups in the phospholipid 
bilayer, and also to the degree of oligomerisation of FhHDM-1 upon association with various 
phospholipid species (9,20). Whilst sphingomyelin and cholesterol are both key components 
of lipid rafts (21,22), FhHDM-1 p2 showed a much higher level of binding to cholesterol 
compared with sphingomyelin. Taken together, these data suggest that FhHDM-1 could bind 
to lipid rafts via interactions with cholesterol.  
 
FhHDM-1 is internalised into endolysosomes and prevent their acidification via inhibition of 
vATPase activity 
Using CSLM we found that Alexa Fluor 488-conjugated FhHDM-1 is internalised into the 
endolysosomal system of macrophages. FhHDM-1 co-localised with cytoplasmic vesicles 
that were visualised with LysoTracker (a lysosomotropic fluorescent dye that concentrates in 
acidic compartments) (see below and Fig. 7A). FhHDM-1 also co-localised with Alexa Fluor 
647-conjugated dextran (when co-incubated with RAW264.7 cells), which further confirms 
that FhHDM-1 enters the endolysosomal pathway (Fig. 5A). 
To investigate its effect on lysosome function, primary human macrophages were 
incubated with recombinant FhHDM-1 or vehicle (PBS) prior to treatment with bacterial LPS 
to induce lysosome formation. Following this, the cells were stained with LysoTracker. In 51 
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% of the PBS-treated macrophages, numerous acidic (LysoTracker-positive) vesicles were 
distributed throughout the cytoplasm following incubation with LPS (Fig. 4A, top panel). In 
contrast, only 25 % of the macrophages pre-treated with FhHDM-1 showed any 
LysoTracker-positive staining in response to LPS with very few acidic compartments visible 
within the cytoplasm (Fig. 4A, bottom panel). In addition, incubation of macrophages with 
FhHDM-1, prior to the addition of E. coli bioparticles conjugated to a pH-sensitive 
fluorogenic dye (that increases in fluorescence with decreasing pH), resulted in a significant 
reduction of fluorescence (36%; p=0.01) in comparison to vehicle (PBS)-treated control cells 
(Fig. 4A). FhHDM-1 p2 exhibited a significantly greater effect on the fluorescence levels 
(66%; p=0.006), while FhHDM-1 nonHP had no effect on fluorescence levels compared to 
control cells. Strikingly, the vATPase inhibitor, folimycin showed a similar level of inhibition 
(59%; p=0.007) to FhHDM-1 p2 (Fig. 4B). Treatment of the cells with NH4Cl, which raises 
lysosomal pH (23), effectively abolished E. coli bioparticle fluorescence (p=0.004). 
Additional experiments using non-opsonised zymosan particles and Alexa Fluor 647-
conjugated dextran showed that FhHDM-1 does not inhibit non-specific phagocytosis or 
endocytosis (Fig. 5B) confirming that the reduced E. coli bioparticle fluorescence resulted 
from FhHDM-induced endolysosomal alkalisation. When macrophages were pre-incubated 
with the cysteine peptidase inhibitor E-64, the inhibitory effect of FhHDM-1 on pH-
dependent E. coli bioparticle fluorescence was abolished (Fig. 4C).  
  
FhHDM-p2, but not the parent FhHDM-1molecule, inhibits vATPase activity. 
The above data shows that FhHDM-1 and FhHDM-p2 prevented the acidification of vesicles 
within the macrophage. We next investigated whether this was due to the inhibition of 
vATPase, which acts as the major regulating factor for the acidification of the endolysosomal 
lumen (24). A lysosome-enriched fraction was prepared from THP-1 or RAW264.7 
macrophages (both showed similar results as described below). The insoluble (membrane; 
Ly-M) component of this fraction was positive for the lysosomal marker, LAMP-1, by 
immunoblot (Fig. S3A). Furthermore, soluble extracts (Ly-S) from this fraction were strongly 
positive for lysosomal cathepsin L activity using the diagnostic fluorescent substrate Z-Leu-
Arg-NHMec (Fig. S3B). The Ly-M fractions were treated with HDMs and assayed for 
ATPase activity. As shown in Figure 6, FhHDM-1 p2 inhibited ATPase activity associated 
with lysosomal membranes (equivalent to vATPase activity) in a concentration-dependent 
manner (IC50 = 0.9 μM). Strikingly, full-length recombinant FhHDM-1, as well as synthetic 
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peptide analogues with a truncated C-terminal amphipathic helix (FhHDM-1 p1), disrupted 
helical structure (FhHDM-1 2Pro) or where the hydrophobic face of the C-terminal 
amphipathic helix has been abolished (FhHDM-1 nonHP), did not inhibit ATPase activity 
even at the highest concentrations tested (Fig. 6). Similar results were obtained using 
membranes isolated from phagosomes purified using latex beads (data not shown).  
 
FhHDM-1 is internalised by macrophages and processed by lysosomal cathepsin L to release 
vATPase inhibitory peptides 
Observations that FhHDM-1-derived peptides inhibit vATPase, while the full-length parent 
molecule does not, may have been attributable to the processing of FhHDM-1 by endogenous 
proteases to release the C-terminal amphipathic helix following internalisation into the 
endolysosome. Our data showing that the cysteine peptidase inhibitor, E-64, could inhibit the 
effect of FhHDM-1 on endolysosome acidification indicated an involvement of this class of 
peptidase (see above). Therefore, full-length FhHDM-1 was incubated with the Ly-S fraction 
(i.e. native contents of macrophage lysosomes) at pH 5.5 and the reaction products were 
analysed by Western blot, using an anti-FhHDM-1 antibody. The blots showed that the 9.2 
kDa band corresponding to full-length recombinant FhHDM-1 had slightly decreased in 
intensity concurrent with the appearance of a number of smaller protein fragments over time 
(Fig. 7B). These fragments were not detected when the reaction was performed in the 
presence of E-64 demonstrating that the full-length protein had been cleaved by a lysosomal 
cysteine peptidase. When the digests were performed using purified human cathepsin L 
(hCatL) endopeptidase (a key cysteine peptidase involved in antigen processing within the 
lysosome) a similar pattern of FhHDM-1 peptide fragments was observed (Fig. 7B).  
 The FhHDM-1 Ly-S digests (0, 2 and 5 h reactions) were analysed by MALDI TOF 
MS (Table 1; Fig. S3C). The only major mass detected in the 0 h reaction was matched to 
full-length recombinant FhHDM-1 (m/z 9232; S/N ratio 341). The intensity of this peak 
decreased considerably after 2 h (not detected) and 5 h (S/N ratio 13). The 5 h digest also 
contained a peak that matched to the recombinant FhHDM-1 minus the C-terminal His-tag 
(m/z 8399; S/N ratio 53), suggesting that processing of the recombinant molecule by 
mammalian peptidases involves initial removal of the His-tag as previously observed during 
processing of FhHDM-1 by FhCL1 (9). The dominant mass detected in the 5 h sample (m/z 
3357; S/N ratio 361) matched to a 29 amino acid C-terminal
 
peptide (minus the His-tag, but 
including the LE added by the expression vector) created by cleavage after Asp
63
 (native 
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peptide numbering). Interestingly, hCatL cleaved FhHDM-1 after Leu
60
 (Table 1) suggesting 
that the C-terminal peptide is processed further by lysosomal aminopeptidases or 
dipeptidyl/tripeptidyl aminopeptidase creating the final cleavage site at Asp
63
 observed 
following digestion with the native lysosomal extract (Ly-S).  
Based on the putative hCatL cleavage site, a 27-residue synthetic peptide (FhHDM-1 
p3) corresponding to the C-terminal region of the native molecule was designed for 
subsequent analysis. This peptide is eight residues shorter at the N-terminus and one residue 
longer at the C-terminal compared to FhHDM p2 (see Fig. 1). Strikingly, FhHDM-1 p3 
inhibited vATPase activity in a concentration-dependent manner as effectively as FhHDM-1 
p2 (Fig. 7C).  
 We also designed a number of synthetic peptides with various N- and C-terminal 
truncations of the amphipathic helix in order to determine the minimal sequence required for 
vATPase inhibition (Fig. 1). However, none of these truncated peptides inhibited vATPase 
activity (Fig. 7C). Of particular note is peptide FhHDM-1 48-70, which is shorter than 
FhHDM-1 p3 at the N-terminal end by only three amino acids (Asn
64
-Leu
65
-Gly
66
) and 
indicates that this motif may be important for vATPase inhibition.   
 
FhHDM-1 inhibits endolysosomal antigen processing and MHC class II antigen presentation 
By preventing the acidification of endolysosomes, via inhibition of vATPase activity, we 
hypothesised that FhHDM-1 would inhibit antigen processing by macrophages as the activity 
of lysosomal proteases and hence the degradation of foreign proteins, is optimal at low pH 
(25). We therefore exposed murine macrophages to the MHC class II antigen casein 
(conjugated to FITC to enable fluorescent in-gel detection), and analysed its degradation by 
SDS-PAGE. Whilst FITC-casein was rapidly degraded in PBS-treated cells, antigen 
degradation was blocked when cells were co-incubated with chloroquine (Clq) a weak base 
known to elevate endolysosomal pH (23). Similarly, FhHDM-1 blocked processing of FITC-
casein in a concentration-dependent manner (Fig. 8A-B). Whilst FhHDM-1 p3 had no 
measurable effect on FITC-casein degradation, FhHDM-1 p2 had a small inhibitory effect at 
higher concentrations that was not seen with peptide nonHP (Fig. 8A-B). It is interesting that 
FhHDM-1 showed a greater inhibitory effect on FITC-casein processing than FhHDM-1 p2 
(Figure 8A) whilst FhHDM-1 p2 had a greater effect than FhHDM-1 on endolysosomal 
alkalization (Figure 4B). Whilst unexpected, these observations are reproducible and may be 
due to differences in the cell type used and assay sensitivity.  
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 We next determined if FhHDM-1 could effect antigen presentation by macrophages. 
To do this we used OVA-specific T cell hybridoma DO-11-10 cells whose proliferative 
response to OVA
323–339
 peptide, presented with MHC class II, can be quantified by measuring 
the levels of secreted interleukin-2 (IL-2) (26,27). DO-11-10 T cells activated in vitro by 
OVA-pulsed murine bone marrow derived macrophages, that were pre-treated with FhHDM-
1, produced significantly less IL-2 (p = 0.001) than those exposed to PBS-treated 
macrophages (Fig. 8C). This effect was not observed when the pre-processed OVA
323–339
 
peptide was used as antigen or when OVA-pulsed macrophages were pre-treated with peptide 
nonHP (data not shown). Therefore, FhHDM-1 modulated the ability of macrophages to 
present antigen.  
 
DISCUSSION 
In response to stimulation by microbes and pro-inflammatory mediators, mammalian innate 
immune cells release an array of host defence peptides (HDPs) that work cooperatively to 
perform broad-spectrum antimicrobial activities (28-30). In addition to their direct 
antimicrobial activity, recent studies have shown that some HDPs (in particular the human 
cathelicidin-derived peptide LL-37) also regulate aspects of innate immunity that can protect 
against excessive inflammation stimulated by the LPS endotoxin (reviewed in (31)). They 
achieve this by interrupting key stages of LPS-mediated cell signalling, thereby preventing 
activation of macrophages and dendritic cells via toll-like receptors (TLR) (32-34). These 
mechanisms include direct binding and sequestration of LPS, preventing its interaction with 
TLRs and blocking the LPS-LPS-binding protein (LBP) interaction, both important early 
stage events in the recognition of microbial infections (35-37). We previously demonstrated 
that the helminth pathogen F. hepatica secreted a small molecule, FhHDM-1, which exerted 
similar effects on LPS signalling, including direct binding of LPS, thereby reducing its 
interaction with both LBP and to the macrophage surface (9).  FhHDM-1 exhibited a striking 
ability to protect mice against LPS-induced inflammation by preventing the release of 
inflammatory mediators from macrophages (9).  We proposed that HDMs are secreted by the 
helminth parasites to protect the host against excessive LPS-induced inflammation that would 
occur following disruption of the intestinal epithelial barrier (and concomitant systemic 
transfer of luminal bacteria), during parasite invasion and migration (9). Thus, by preventing 
the activation of innate immune responses normally induced by LPS, the helminth enhances 
the survival of the host and, accordingly, its own longevity. However, since we discovered 
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that HDMs are also rapidly internalised into macrophages we surmised that they have an 
additional, novel, mechanism of action that influences macrophage function. 
 Confocal microscopy revealed that the initial interaction of FhHDM-1 with 
macrophages occurs through association with lipid rafts on the cell surface. Despite extensive 
trypsinization of cell surface proteins, the interaction between FhHDM-1 and the macrophage 
was not affected, indicating that FhHDM-1 binds to non-proteinaceous lipid raft components. 
One putative binding partner for FhHDM-1 is cholesterol, a key sterol component of lipid 
rafts (22), since this molecule contains a cholesterol-binding motif, (L/V-[X]1-5-Y-[X]1-5-R/K, 
spanning residues V
45
TKAYEKAR
53
) that is highly conserved across all known cholesterol-
binding proteins (38). However, FhHDM-1 p2, which lacks the cholesterol binding motif due 
to an N-terminal truncation, nevertheless binds cholesterol in a concentration-dependent 
manner. While the motif may enhance the specificity of the FhHDM-1-cholesterol 
interaction, or perhaps dictate the orientation of HDM-binding at the cell surface, it alone is 
clearly not essential for cholesterol-binding.  
It is also probable that FhHDM-1 binds to lipid rafts via the HDM C-terminal 
amphipathic helix since a similar structural element of the tyrosine kinase interacting protein 
(Tip) of Herpesvirus saimiri has been shown to target Tip to lipid rafts and directs its 
lysosomal trafficking (39). The human cathelicidin-derived peptide, LL-37, also interacts 
with lipid rafts on the cell surface prior to endocytosis by CHO-K1 cells (40). However, LL-
37 cannot bind to cholesterol (indeed its presence strongly reduces the ability of LL-37 to 
interact with phospholipid membranes; 41,42) and, therefore, more likely interacts with the 
P2X7 receptor, which is found within lipid rafts (43). While LL-37 directly induces the 
release of cytokines from monocytes (notably IL-1β), via direct activation of P2X7 receptors 
(44), we have found that FhHDM-1 p2 does not activate this receptor (data not shown). This 
highlights key functional differences between the two molecules and how they interact with 
macrophages.  
Following initial binding to lipid rafts, FhHDM-1 was internalised into LysoTracker-
positive vesicles and co-localised with fluorescently-labelled dextran, which is known to 
enter cells via the endolysososmal system (45). Pre-incubation of macrophages with FhHDM-
1 led to a reduction of fluorescence associated with E. coli bioparticles that were conjugated 
to a pH-sensitive fluorogenic dye such that they only fluoresce upon delivery into acidified 
phagolysosomal vesicles. Experiments using non-opsonised zymosan particles and 
fluorescently-labelled dextran confirmed that the reduced E. coli bioparticle fluorescence was 
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not simply due to inhibition of non-specific uptake by FhHDM-1. The effect of FhHDM-1 on 
lysosomal pH was also demonstrated using the pH sensitive dye, LysoTracker as pre-
incubation of macrophages with FhHDM-1 significantly reduced the numbers of 
LysoTracker-positive (acidic) vesicles throughout the cell in response to LPS stimulation. 
Collectively, these experiments show that FhHDM-1 causes the collapse of the 
endo/phagolysosomal pH gradient in macrophages. Proteomics analysis of FhHDM-1-treated 
primary human macrophages supports this finding, indicating that the parasite molecule has a 
suppressive effect on components of the lysosomal pathway (M.W. Robinson and R. 
Alvarado, unpublished data). 
Acidification of endolysosomal compartments is primarily mediated by vATPase, a 
transmembrane complex comprised of cytosolic (V1) and membrane bound (V0) subunits 
(46). We found that FhHDM-1 p2 inhibited ATPase activity associated with macrophage 
endolysosomal membranes in a concentration-dependent manner. Since in assembled, 
functional vATPase complexes, ATP hydrolysis by the cytoplasmic V1 domain drives proton 
transport through the membrane bound V0 domain from the cytoplasm to the endolysosomal 
lumen (46) prevention of this process provides a novel, and direct, biochemical mechanism 
by which the secreted parasite molecule impairs acidification of endolysosomal vesicles. 
Consistent with the data derived from our E. coli bioparticle assays, vATPase inhibition 
required an intact HDM amphipathic helix (peptide nonHP was non-inhibitory), which 
further highlights the importance of the C-terminal tail of FhHDM-1. It is interesting to note 
that the human salivary HDP histatin-5, which possesses anti-Leishmania activity also targets 
a proton pump, the mitochondrial F1F0-ATPase (ATP synthase), of the parasite (47). 
However, this peptide does not adopt an amphipathic structure (48) and does not display 
primary sequence identity with FhHDM-1 p2, although both peptides possess short α-helices.  
While the full-length parent FhHDM-1 molecule was capable of uncoupling 
endolysosomal acidification in macrophages, it was unable to directly inhibit vATPase 
activity. For this, FhHDM-1 needs to be proteolytically processed within the macrophage. 
MALDI-TOF MS analysis revealed that processing of FhHDM-1 by native lysosomal 
peptidases released a 29-residue C-terminal fragment (m/z 3357) created by cleavage after 
Asp
63
. Purified native human cathepsin L released an almost identical 30-residue C-terminal 
fragment (m/z 3400) from FhHDM-1 created by cleavage after Leu
60
, suggesting that this 
enzyme is responsible for FhHDM-1 cleavage in vivo. A 27-residue synthetic peptide 
analogue (FhHDM-1 p3) based on the sequence of the released peptides inhibited 
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macrophage vATPase activity, in a concentration-dependent manner, as effectively as the 34-
residue peptide FhHDM-1 p2. Experiments using various N- and C-terminal truncations of 
FhHDM-1 p3, showed that FhHDM-1 p3 itself was the shortest peptide tested that retained 
vATPase inhibitory activity and highlighted an Asn
64
-Leu
65
-Gly
66 
motif located just upstream 
of the amphipathic helix, as important for inhibition. It appears that following raft-dependent 
endocytosis, FhHDM-1 is processed by macrophage lysosomal cathepsin L to release a ~27-
residue peptide from its C-terminus that directly inhibits vATPase leading to impaired 
acidification of endolysosomal compartments. Our observation that pre-incubation of 
macrophages with the cysteine peptidase inhibitor, E-64, abolished FhHDM-1-induced 
endolysosomal alkalisation supports this hypothesis.   
 One of the major roles of macrophages is to present peptides derived from exogenous 
antigens in the context of MHC class II to CD4
+
 T cells (1). Efficient degradation of 
antigenic peptides by peptidases within endolysosomal compartments can only occur at low 
pH (pH 5.0-5.5) (25) and agents such as chloroquine, that elevate the pH of the 
endolysosomal lumen, have a significant suppressive effect on antigen processing and 
subsequent presentation (49). Indeed, we found that FhHDM-1-induced endolysosomal 
alkalisation led to the inhibition of MHC class II antigen (FITC-casein) processing by 
macrophages and significantly reduced presentation of OVA to CD4
+
 T cells. Type 2 
cystatins secreted by various parasitic nematodes have been shown to impair MHC class 
II-restricted antigen processing, via inhibition of mammalian lysosomal cysteine peptidases 
(cathepsins B, H, L, S and asparaginyl endopeptidase) in antigen presenting cells (50,51). 
However, given that the low pH microenvironment within the endolysosomal lumen ensures 
the activity of around 40 types of acid hydrolases, including peptidases, lipases, 
phosphatases, nucleases and glycosidases (46), and that pH regulates the release of 
internalised ligands from their endosomal receptors (52), is it probable that FhHDM-1-
induced uncoupling of endolysosomsal acidification will have a broad span of effects on 
macrophage function.  
 The targeting of vATPase by HDMs represents a novel mechanism of 
immunomodulation by a secreted parasite molecule. The inhibition of antigen processing and 
presentation by macrophages by uncoupling endolysosomal acidification has not previously 
been described as a mechanism by which a helminth parasite evades the protective responses 
of the host (see Fig. 9 for an overview of this process). In the context of parasite infection, 
our data suggest that the secretion of FhHDM-1 by juvenile worms would suppress the 
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development of parasite-specific immune responses generated in response to subsequent 
developmental stages. The broader, detrimental, consequences of this would be to prevent the 
development of antigen-specific responses to unrelated third-party antigens, such as a co-
infecting microbial pathogen or delivery of a vaccine, as is often the case for human 
populations in areas of endemic helminth infection. On the other hand, a deeper 
understanding of the mechanism of action of HDMs could be of great benefit, potentially 
providing a therapeutic where the inhibition of vATPase or lysosomal acidification halts the 
progress of pathology, such as in cancer or osteoarthritis (53,54).      
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FIGURE LEGENDS 
Figure 1. Primary sequence alignment of the HDMs used in the present study. The 
region forming the 21-residue amphipathic helix of FhHDM-1 and the mutated residues in 
peptides FhHDM-1 nonHP and FhHDM-1 2Pro are boxed in grey. The putative cholesterol-
binding motif is underlined. 
 
Figure 2. FhHDM-1 binds to the macrophage plasma membrane via interaction with 
lipid rafts. (A) FhHDM-1-treated (10 µg/ml) or PBS-treated (control) primary human 
macrophages were immunostained for the presence of FhHDM-1 (green). Cells were also 
stained with DAPI (blue) to detect nuclei or with the lipophilic dye DiI (red) to visualise the 
plasma membrane and examined by CLSM. FhHDM-1 fluorescence was observed around the 
periphery of the cells in association with the plasma membrane. Scale bars = 3 m. (B) 
Primary human macrophages were treated with FhHDM-1 (10 µg/ml) for 2 h then 
immunostained for the presence of FhHDM-1 (green) and stained with Alexa Fluor 594-CT-
B conjugate (lipid raft marker; red) and with DAPI (blue) to detect nuclei. Cells were 
examined with a DeltaVisionOMX 3D-Structured Illumination Microscope
®
. Strong co-
localisation of FhHDM-1 with CT-B (yellow) suggests that FhHDM-1 interacts specifically 
with lipid rafts within the plasma membrane of primary human macrophages. Scale bar = 3 
m. 
 
Figure 3. FhHDM-1 binds membranes via selective interaction with phospholipids and 
cholesterol. (A) RAW264.7 macrophages were treated with FhHDM-1 (20 µg/ml) for 2 h. 
Cell membranes were then prepared and either washed with Na2CO3 or solubilised with 
TX100 and the extracts subjected to SDS-PAGE. Western blots were probed with antibodies 
specific for FhHDM-1, calnexin or actin. (B) RAW264.7 macrophages were incubated with 
(dashed line) or without (solid line) trypsin and the binding of Cy5-labelled FhHDM-1 (10 
g/ml) to the cell surface determined by FACS following 30 min incubation at 4°C. The 
macrophage markers CD11b and F4/80 were used as positive controls for trypsinization. (C) 
HDMs (50 µM) were incubated with LUVs (as model phospholipid membranes) for 2 h and 
separated by centrifugation on sucrose gradients. LUVs and bottom fractions were analysed 
by SDS-PAGE and visualized by silver staining. LL-37 and BSA were used as positive and 
negative controls respectively. (D) Phospholipid-coated microtiter wells were incubated with 
serial dilutions of biotinylated FhHDM-1 p2 for 90 min and assessed for binding by detection 
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with streptavidin-AP. Data are the mean absorbance values  SD of three independent 
experiments.   
 
Figure 4. FhHDM-1 prevents the acidification of endolysosomes. (A) Primary human 
macrophages were pre-incubated with FhHDM-1 (10 µg/mL) or PBS for 20 h and then 
treated with bacterial LPS (50 ng/mL) for 2 h to induce lysosome formation. Cells were then 
stained for lysosomes (red). Scale bar = 10 m. (B) Primary human macrophages were 
incubated with HDMs (10 µg/mL) for 20 h prior to the addition of E. coli fluorescent 
bioparticles. FhHDM-1 and FhHDM-1 p2 significantly inhibited the pH-dependent 
fluorescence of the bioparticles whilst peptide FhHDM-1 nonHP did not. The vATPase 
inhibitor folimycin (1 µM) showed a similar level of inhibition to FhHDM-1 p2. NH4Cl (20 
mM), which raises lysosomal pH, effectively abolished E. coli bioparticle fluorescence. Data 
are the mean  SD of three separate experiments. (C) RAW264.7 macrophages were 
incubated with or without the cysteine peptidase inhibitor E-64 (10 M) for 30 min prior to 
treatment with PBS or FhHDM-1 (10 g/ml) for 3 h. Fluorescent E. coli bioparticles were 
then added to the cells for 2 h at 37°C. The inhibition of the pH-dependent bioparticle 
fluorescence shown by FhHDM-1 was abolished when the cells were pre-treated with E-64. 
Data are the mean  SD of two separate experiments.  
 
Figure 5. FhHDM-1 does not inhibit non-specific phagocytosis by macrophages. (A) 
RAW264.7 macrophages were incubated ± Alexa Fluor-488-conjugated FhHDM-1(50 
µg/mL) for 2 h prior to the addition of Alexa Fluor 647-conjugated dextran (10 µg/mL for 2 
h). The cells were then analysed by confocal microscopy. Treatment with FhHDM-1 (green 
fluorescence) had no effect on phagocytosis of the dextran (red fluorescence). Co-localisation 
of dextran and FhHDM-1 can be seen as yellow fluorescence. Scale bar = 5 m. (B) 
RAW264.7 macrophages were treated with recombinant 10 µg/mL FhHDM-1 for 2 h or 20 h 
prior to the addition of non-opsonised zymosan particles. Whilst cytochalasin D (Cy-D) 
strongly inhibited zymosan uptake, FhHDM-1 had no significant effect on phagocytosis of 
the zymosan particles. Data are the mean  SD of three separate experiments. 
 
Figure 6. FhHDM-p2, but not the parent FhHDM-1 molecule, inhibits vATPase activity. 
The effect of HDMs on ATPase activity associated with lysosomal membranes prepared from 
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RAW264.7 macrophages was assessed using the ATPase Assay kit (Innova Biosciences). 
Data are the mean values  SD of three independent experiments.  
 
Figure 7. FhHDM-1 is internalised by macrophages and processed by lysosomal 
cathepsin L. (A) RAW264.7 macrophages were incubated with 10 µg/mL Alexa Fluor 488-
conjugated FhHDM-1 (HDM-488; green fluorescence), stained with LysoTracker (red 
fluorescence) and examined by CLSM. Co-localisation of FhHDM-1 with LysoTracker 
(yellow fluorescence) shows that FhHDM-1 enters the endolysosmal pathway in 
macrophages. Scale bar = 5 m. (B) To investigate whether lysosomal peptidases can process 
FhHDM-1, 25 g recombinant FhHDM-1 was incubated with 1 g native lysosomal contents 
(Ly-S) or purified human cathepsin L (hCatL) at pH 5.5. Reactions were performed for up to 
5 h at 37 °C and stopped by the addition of E-64 (10 μM). Samples were analysed on 4–12 % 
Bis-Tris gels and blots were probed with an anti-FhHDM-1 antibody. 5+E64; 5 h digest 
performed in the presence of 10 μM E-64. (C) The 5 h Ly-S digest shown in (B) was 
analysed by MALDI-TOF MS (Figure S3C; Table 1). The dominant mass detected (m/z 
3357) matched to a 29-residue C-terminal fragment of FhHDM-1 created by cleavage after 
Asp
63
. A synthetic peptide FhHDM-1 p3, based on this sequence, inhibited macrophage 
vATPase activity in a concentration-dependent manner, similar to FhHDM-1 p2. Truncated 
peptides based on FhHDM-1 p3 (see Figure 1) did not inhibit vATPase. Data are the mean  
SD of three separate experiments.  
 
Figure 8. FhHDM-1 inhibits endolysosomal antigen processing and MHC II antigen 
presentation. (A) SDS-PAGE of RAW264.7 macrophages that phagocytosed FITC-casein 
for 3 h in the presence or absence of HDMs (5, 20 and 50 g/ml) and 20 M chloroquine 
(Clq). (B) Fluorescent imaging of the gels and densitometry shows the amount of 
unprocessed intracellular FITC-casein as a percentage of the PBS-treated control cells. Data 
are representative of three independent experiments. (C) IL-2 production by DO-11-10 T 
cells in response to activation by OVA-pulsed BMDMs pre-treated for 2 h with FhHDM-1 
(10, 50 and 100 g/ml).  
 
Figure 9. Overview of the proposed mechanism of action of FhHDM-1. Exogenous 
antigen is taken up by macrophages and routed to the endocytic pathway where it is degraded 
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by lysosomal proteases and loaded to MHC class II for presentation to CD4+ T cells at the 
cell surface. (1) Endolysosomal acidification is mediated by vATPase which creates optimal 
conditions for lysosomal protease activity. (2) Following entry into the endolysosomal 
compartments, FhHDM-1 is cleaved by lysosomal proteases to release the C-terminal 
fragment (containing an amphipathic helix, shown in red), which then inhibits vATPase 
activity. The resulting endolysosomal alkalisation leads to an inhibition of antigen processing 
and MHC class II presentation. 
 
Supplemental Data 
 
Fig. S1. Peptide molar concentrations. The molar concentrations for HDM peptides 
(derived from the µg/ml amounts used in this study) are shown. 
 
Fig. S2. Binding of FhHDM-1 to the macrophage surface. (A) RAW264.7 macrophages 
were incubated with 20 ug/ml (solid line) or 50 ug/ml (dashed line) of recombinant FhHDM-
1 or FhCL1 for 1 h at 4°C. The filled grey histogram shows untreated cells. Bound 
recombinants were detected with a mouse anti-His antibody and goat anti-mouse Alexa Fluor 
488. (B) RAW264.7 macrophages were treated with 20 µg/ml FhHDM-1 or FhCL1 for 1 h 
then stained using a mouse anti-His antibody. Cells were also stained with DAPI (blue) to 
detect nuclei or with the phalloidin (red) to visualise the actin cytoskeleton and examined by 
CLSM. FhHDM-1 staining (green fluorescence) can be seen along the plasma membrane. 
Scale bars = 5 m. (C) THP-1 macrophages were treated with FhHDM-1 (20 µg/ml) for 2 h. 
Cell membranes were then prepared and either washed with Na2CO3 or solubilised with 
TX100 and the extracts subjected to SDS-PAGE. Western blots were probed with antibodies 
specific for FhHDM-1, calnexin or actin. 
 
Fig. S3. Biochemical characterisation of macrophage lysosomal fractions and processing 
of FhHDM-1 by the Ly-S fraction. (A) Western blot of RAW264.7 macrophage lysosomal 
membranes (Ly-M), soluble lysosomal contents (Ly-S) and a cell cytoplasm fraction (Cyt) 
probed with an anti-LAMP-1 antibody. (B) Lysosomal cathepsin activity within the soluble 
Ly-S fraction was confirmed using the fluorogenic cathepsin substrate Z-Leu-Arg-NHMec. 
The assay was performed at pH 5.5 and peptidolytic activity was measured by monitoring the 
release of the fluorogenic leaving group (-NHMec) over 30 min at 37°C ± the cysteine 
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peptidase inhibitor E-64 (10 M). (C) MALDI TOF MS analysis of the FhHDM-1 Ly-S 
digest. The 5 h Ly-S digest of FhHDM-1 (Figure 7B) was analysed by MALDI-TOF MS. 
The dominant mass detected (m/z 3357) was matched to a 29-residue C-terminal fragment of 
FhHDM-1 created by cleavage after Asp
63
.  
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Table 1. MALDI TOF MS analysis of FhHDM-1 Ly-S and hCatL digests.  
Digests of FhHDM-1 with Ly-S and hCatL (0 h, 2 h and 5 h) were analysed by MALDI TOF MS. The major masses 
detected correspond to full-length recombinant FhHDM-1 (m/z 9272) and C-terminal peptide fragments released following 
cleavage by Ly-S (m/z 3329) and hCatL (m/z 3400). 
1
recombinant FhHDM-1 numbering. 
 
     Digest time point 
                0 h             2 h            5 h 
Sample 
m/z 
submitted 
m/z 
matched 
Delta 
(Da) 
HDM 
peptide
1
 
Area S/N Area S/N Area S/N 
           
Ly-S 
digest 
9232 9272 +40 1-79 736,009 341 ND ND 21,109 13 
3357 3329 -28 44-73 8,752 55 288 17 26,911 361 
           
hCatL 
digest 
9229 9272 +43 1-79 67,977 94 7,732 15 ND ND 
3400 3400 0 42-71 ND ND 37,293 70 6,422 7 
 
